<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653364</url>
  </required_header>
  <id_info>
    <org_study_id>CP40559</org_study_id>
    <secondary_id>2018-002154-70</secondary_id>
    <nct_id>NCT03653364</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to &lt; 1 Year With Influenza-Like Symptoms</brief_title>
  <official_title>A Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients From Birth to &lt; 1 Year With Influenza-Like Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in
      healthy pediatric participants from birth to &lt;1 year with influenza like symptoms
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event (SAE) is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/ incapacity, is a congenital anomaly/ birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Baloxavir Marboxil and S-033447</measure>
    <time_frame>Day 2 and Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration to Time Curve from Time 0 to Infinity (AUC0-inf) of baloxavir marboxil and S-033447</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of baloxavir marboxil and S-033447</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of baloxavir marboxil and S-033447</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Half-Life (T1/2) of baloxavir marboxil and S-033447</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of Influenza Signs and Symptoms</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Time to alleviation of influenza signs and symptoms is defined as the length of time taken from the start of treatment to the point at which all of the following criteria are met and remain so for at least 21.5 hours:
A score of 0 (no problem) or 1 (minor problem) for cough and nasal symptoms (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale [CARIFS])
A &quot;yes&quot; response to the following question on the CARIFS: &quot;Since the last assessment has the subject been able to return to day care/school, or resume his or her normal daily activity in the same way as performed prior to developing the flu?&quot;
First return to afebrile state (tympanic temperature ≤37.2 degree Celsius [°C])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Fever</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>Length of time taken by participants to return to afebrile state [tympanic temperature ≤ 37.2°C] and remaining so for at least 21.5 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Symptoms</measure>
    <time_frame>Up to Day 15</time_frame>
    <description>The efficacy of baloxavir marboxil is evaluated by duration of symptoms i.e., alleviation of all symptoms as defined by a score of 0 [no problem] or 1 [minor problem] and remaining so for at least 21.5 hours, for all 18 symptoms specified in the CARIFS questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Normal Health and Activity</measure>
    <time_frame>Up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Influenza-Related Complications</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The influenza related complications include death, hospitalization, radiologically confirmed pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures, myositis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Antibiotics</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding by Virus Titer and by RT-PCR</measure>
    <time_frame>Day 1 - Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Influenza Virus Titer and in the Amount of Virus RNA (RT-PCR) at Day 2, 4, 6, 10, 15, 29</measure>
    <time_frame>Baseline, Day 2, 4, 6, 10, 15, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Positive Influenza Virus Titer and Positive by RT-PCR at Day 2, 4, 6, 10, 15, 29</measure>
    <time_frame>Day 2, 4, 6, 10, 15, 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve in Virus Titer and in the Amount of Virus RNA (RT-PCR)</measure>
    <time_frame>Day 1 - Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of baloxavir marboxil on Day 1 (based on body weight and age).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir Marboxil</intervention_name>
    <description>Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age.
Participants will be recruited in parallel to the following three cohorts:
Cohort I: ≥ 3 months to &lt; 12 months old (minimum 8 participants): 2 mg/kg
Cohort II: ≥ 4 weeks to &lt; 3 months old (minimum 4 patients): 1 mg/kg
Cohort III: birth to &lt; 4 weeks old (minimum 4 patients): 1 mg/kg</description>
    <arm_group_label>Baloxavir Marboxil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from birth to &lt; 1 year at screening

          -  Written informed consent for study participation obtained from participant's parents
             or legal guardian

          -  Parent/guardian willing and able to comply with study requirements, in the
             investigator's judgment

          -  Participants with a diagnosis of influenza virus infection confirmed by the presence
             of all of the following:

          -  Fever ≥ 38°C (tympanic temperature) at screening or within the 4 hours prior if
             antipyretics were taken.

          -  At least one respiratory symptom (either cough or coryza)

          -  Positive prescreening influenza test (RIDT or PCR) performed within 24 hours of
             screening

          -  Participants with a negative prescreening COVID-19 test (PCR)

          -  The time interval between the onset of symptoms and screening is ≤ 96 hours (the onset
             of symptoms is defined as the time when body temperature first exceeded 37.5°C if
             known, or the time when the first symptom was noticed by the parent or caregiver)

        Exclusion Criteria:

          -  Hospitalized for complications of influenza or significant comorbidities

          -  Concurrent infections requiring systemic antiviral therapy at screening

          -  Require, in the opinion of the investigator, any of the prohibited medication during
             the study

          -  Preterm neonates (born at &lt; 37 weeks gestation) and/or weighing &lt; 2.5 kg at screening

          -  Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine
             within 2 weeks prior to screening

          -  Immunization with a live/attenuated influenza vaccine during the 2 weeks prior to
             screening

          -  Concomitant treatment with steroids or other immuno-suppressant therapy

          -  Known HIV infection or other immunosuppressive disorder

          -  Uncontrolled renal, vascular, neurologic or metabolic disease (e.g., diabetes, thyroid
             disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or
             participants with known chronic renal failure

          -  Active cancer at any site

          -  History of organ transplant

          -  Known hypersensitivity to study drug (i.e., baloxavir marboxil) or to acetaminophen

          -  Participation in a clinical trial within 4 weeks or five half-lives of exposure to an
             investigational drug prior to screening, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number: CP40559 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uni of Alabama At Birmingham; Departement of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro, P.A.</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Khruz Biotechnology Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver, Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Avanza Medical Research Center</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Usf Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago;Division of Infectious Disease</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric Research Center</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Childrens Health Research Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oak Cliff Research Company, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercury Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036-3316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICIMED Instituto de Investigación en Ciencias Médicas</name>
      <address>
        <city>San Jose</city>
        <zip>10108</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsingin yliopistollinen keskussairaala; Uusi Lastensairaala</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>TAYS Lastenklinikka; Lasten lääketutkimuskeskus Peetu</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turun Yliopistollinen keskussairaala; Lasten ja nuorten klinikka</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clalit Health Services- Pediatric Ambulatory Clinic; Pediatric Ambulatory Clinic</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4931807</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico; Infectology</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policentro de Salud de Juan Diaz</name>
      <address>
        <city>Panama</city>
        <zip>0816-06812</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno-Zakazny; Oddział Pediatrii, Chorób Infekcyjnych i Hepatologii</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Vitamed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZLA Michalkowice Jarosz i partnerzy Spolka Lekarska</name>
      <address>
        <city>Siemianowice Śląskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Zespol Publicznych Zakladow Opieki Zdrowotnej im. Dzieci Warszawy w Dziekanowie Lesnym</name>
      <address>
        <city>Łomianki</city>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Salmed</name>
      <address>
        <city>Łęczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The scientific-research institute of epidemiology; Infectious clinical hospital №2 of Moscow H.D.</name>
      <address>
        <city>Moskva</city>
        <state>Moskovskaja Oblast</state>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LCS Clinical Research Unit; Clinical Research</name>
      <address>
        <city>Cosmo CITY</city>
        <zip>2188</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CRISMO; Clinical Research</name>
      <address>
        <city>Germiston</city>
        <zip>1401</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Peermed Clinical Trial Centre</name>
      <address>
        <city>Kempton Park</city>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan Medical Center</name>
      <address>
        <city>Polokwane</city>
        <zip>0699</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Pholosho Netcare; Netcare Hospital</name>
      <address>
        <city>Polokwane</city>
        <zip>0699</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre; Clinical Research</name>
      <address>
        <city>Pretoria</city>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinix Botshelong; Empilweni Private Hospital</name>
      <address>
        <city>Vosloorus EXT 9</city>
        <zip>1475</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research SA pty Ltd</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago (CHUS); Area Asistencial Integrada de Pediatría</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Pediatria</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health (Children's Hospital); Pediatrics</name>
      <address>
        <city>Payathai</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

